- Home
- IGMS vs ADAG Comparison
IGMS vs ADAG Comparison
Compare IGMS & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- ADAG
- Stock Information
- Founded
- IGMS 1993
- ADAG 2011
- Country
- IGMS United States
- ADAG China
- Employees
- IGMS N/A
- ADAG N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- IGMS Health Care
- ADAG Health Care
- Exchange
- IGMS Nasdaq
- ADAG Nasdaq
- Market Cap
- IGMS 82.1M
- ADAG 81.9M
- IPO Year
- IGMS 2019
- ADAG 2021
- Fundamental
- Price
- IGMS $1.13
- ADAG $1.60
- Analyst Decision
- IGMS Hold
- ADAG Strong Buy
- Analyst Count
- IGMS 8
- ADAG 1
- Target Price
- IGMS $6.14
- ADAG $8.00
- AVG Volume (30 Days)
- IGMS 155.8K
- ADAG 15.4K
- Earning Date
- IGMS 05-20-2025
- ADAG 03-24-2025
- Dividend Yield
- IGMS N/A
- ADAG N/A
- EPS Growth
- IGMS N/A
- ADAG N/A
- EPS
- IGMS N/A
- ADAG N/A
- Revenue
- IGMS $2,679,000.00
- ADAG $103,204.00
- Revenue This Year
- IGMS $121.76
- ADAG $6,488.89
- Revenue Next Year
- IGMS $46.83
- ADAG $57.50
- P/E Ratio
- IGMS N/A
- ADAG N/A
- Revenue Growth
- IGMS 25.77
- ADAG N/A
- 52 Week Low
- IGMS $0.92
- ADAG $1.33
- 52 Week High
- IGMS $22.50
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- IGMS 39.53
- ADAG 51.88
- Support Level
- IGMS $1.11
- ADAG $1.51
- Resistance Level
- IGMS $1.40
- ADAG $1.74
- Average True Range (ATR)
- IGMS 0.11
- ADAG 0.10
- MACD
- IGMS -0.01
- ADAG 0.03
- Stochastic Oscillator
- IGMS 5.56
- ADAG 61.84
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.